@jhesonc.bsky.social
Reposted
Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST | Journal of Clinical Oncology ascopubs.org/doi/10.1200/... @n8pennell.bsky.social @ascocancer.bsky.social @oncoalert.bsky.social
April 5, 2025 at 7:20 PM
Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST | Journal of Clinical Oncology ascopubs.org/doi/10.1200/... @n8pennell.bsky.social @ascocancer.bsky.social @oncoalert.bsky.social
@prof-ali-g.bsky.social
Hi Ali. Any ideas where I can read the latest recommendations/guidance re the ctdna pilot? I think you said there’d be an update this week re its introduction to the routine testing panel and the implications for tissue. Thanks
Hi Ali. Any ideas where I can read the latest recommendations/guidance re the ctdna pilot? I think you said there’d be an update this week re its introduction to the routine testing panel and the implications for tissue. Thanks
April 2, 2025 at 5:33 PM
@prof-ali-g.bsky.social
Hi Ali. Any ideas where I can read the latest recommendations/guidance re the ctdna pilot? I think you said there’d be an update this week re its introduction to the routine testing panel and the implications for tissue. Thanks
Hi Ali. Any ideas where I can read the latest recommendations/guidance re the ctdna pilot? I think you said there’d be an update this week re its introduction to the routine testing panel and the implications for tissue. Thanks
Reposted
LAURA OS update (LBA4)
👉 Now 31% maturity
❇️ 78% in PBO grp got Osi at PD
❇️ Improved PFS2
❇️ Trend ⬆️ OS HR 0.67, not significant
💭 Confirm activity of Osi
💭 Crossover impacts OS difference
💭 Final maturity due @ 60%
💭 Surprised 1/3 Osi pts = no further treatment at PD
#ELCC25
👉 Now 31% maturity
❇️ 78% in PBO grp got Osi at PD
❇️ Improved PFS2
❇️ Trend ⬆️ OS HR 0.67, not significant
💭 Confirm activity of Osi
💭 Crossover impacts OS difference
💭 Final maturity due @ 60%
💭 Surprised 1/3 Osi pts = no further treatment at PD
#ELCC25
March 28, 2025 at 2:10 PM
LAURA OS update (LBA4)
👉 Now 31% maturity
❇️ 78% in PBO grp got Osi at PD
❇️ Improved PFS2
❇️ Trend ⬆️ OS HR 0.67, not significant
💭 Confirm activity of Osi
💭 Crossover impacts OS difference
💭 Final maturity due @ 60%
💭 Surprised 1/3 Osi pts = no further treatment at PD
#ELCC25
👉 Now 31% maturity
❇️ 78% in PBO grp got Osi at PD
❇️ Improved PFS2
❇️ Trend ⬆️ OS HR 0.67, not significant
💭 Confirm activity of Osi
💭 Crossover impacts OS difference
💭 Final maturity due @ 60%
💭 Surprised 1/3 Osi pts = no further treatment at PD
#ELCC25
Reposted
COCOON: mitigating cutaneous toxicity of Amivantamab
✅ 60% reduction in Gr2+ dermatology AE
✅ Reduction scalp issues+ paronychia
✅ Fewer Ami dose amendments needed
💭 This regimen should be instigated immediately for any patient starting Amivantamab based therapy
#ELCC25
✅ 60% reduction in Gr2+ dermatology AE
✅ Reduction scalp issues+ paronychia
✅ Fewer Ami dose amendments needed
💭 This regimen should be instigated immediately for any patient starting Amivantamab based therapy
#ELCC25
March 27, 2025 at 4:05 PM
COCOON: mitigating cutaneous toxicity of Amivantamab
✅ 60% reduction in Gr2+ dermatology AE
✅ Reduction scalp issues+ paronychia
✅ Fewer Ami dose amendments needed
💭 This regimen should be instigated immediately for any patient starting Amivantamab based therapy
#ELCC25
✅ 60% reduction in Gr2+ dermatology AE
✅ Reduction scalp issues+ paronychia
✅ Fewer Ami dose amendments needed
💭 This regimen should be instigated immediately for any patient starting Amivantamab based therapy
#ELCC25
Reposted
Great ROS1 TKI summary slide from Julian Mazieres
March 27, 2025 at 4:07 PM
Great ROS1 TKI summary slide from Julian Mazieres
Reposted
MARIPOSA final OS analysis
❇️ Significant HR 0.75
❇️ 9% 3yr benefit
❇️ Projected mOS 4 years
❇️ Longer control of CNS disease
❗️At the cost of toxicity
❗️No data on duration of toxicity
❗️PROM and QoL data important
More effective than Osimertinib
Most suitable for higher risk pts
#ELCC25
❇️ Significant HR 0.75
❇️ 9% 3yr benefit
❇️ Projected mOS 4 years
❇️ Longer control of CNS disease
❗️At the cost of toxicity
❗️No data on duration of toxicity
❗️PROM and QoL data important
More effective than Osimertinib
Most suitable for higher risk pts
#ELCC25
March 26, 2025 at 4:07 PM
MARIPOSA final OS analysis
❇️ Significant HR 0.75
❇️ 9% 3yr benefit
❇️ Projected mOS 4 years
❇️ Longer control of CNS disease
❗️At the cost of toxicity
❗️No data on duration of toxicity
❗️PROM and QoL data important
More effective than Osimertinib
Most suitable for higher risk pts
#ELCC25
❇️ Significant HR 0.75
❇️ 9% 3yr benefit
❇️ Projected mOS 4 years
❇️ Longer control of CNS disease
❗️At the cost of toxicity
❗️No data on duration of toxicity
❗️PROM and QoL data important
More effective than Osimertinib
Most suitable for higher risk pts
#ELCC25
Reposted
SAVANNAH: Osi+Savolitinib in MET amp/OE EGFR+ post 1L Osi
👉 Protocol evolved over time
👉 34% pts have MET OE/amp
❇️ ORR 56%; mDOR 9.9m
❇️ mPFS 7.5m
❗️32% Gr3+ AE: oedema, N&V, diarr
❗️Dose amendments mainly for Savo
💭 Good that includes MET OE
💭 Expected side effects, not insignificant
👉 Protocol evolved over time
👉 34% pts have MET OE/amp
❇️ ORR 56%; mDOR 9.9m
❇️ mPFS 7.5m
❗️32% Gr3+ AE: oedema, N&V, diarr
❗️Dose amendments mainly for Savo
💭 Good that includes MET OE
💭 Expected side effects, not insignificant
March 26, 2025 at 4:30 PM
SAVANNAH: Osi+Savolitinib in MET amp/OE EGFR+ post 1L Osi
👉 Protocol evolved over time
👉 34% pts have MET OE/amp
❇️ ORR 56%; mDOR 9.9m
❇️ mPFS 7.5m
❗️32% Gr3+ AE: oedema, N&V, diarr
❗️Dose amendments mainly for Savo
💭 Good that includes MET OE
💭 Expected side effects, not insignificant
👉 Protocol evolved over time
👉 34% pts have MET OE/amp
❇️ ORR 56%; mDOR 9.9m
❇️ mPFS 7.5m
❗️32% Gr3+ AE: oedema, N&V, diarr
❗️Dose amendments mainly for Savo
💭 Good that includes MET OE
💭 Expected side effects, not insignificant
Reposted
Honoured to co-first author this important paper with Prof Herbst and the entire team looking at MRD in the ADAURA trial. www.nature.com/articles/s41...
Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer - Nature Medicine
Exploratory post hoc analysis of molecular residual disease from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer shows that mol...
www.nature.com
March 19, 2025 at 2:34 AM
Honoured to co-first author this important paper with Prof Herbst and the entire team looking at MRD in the ADAURA trial. www.nature.com/articles/s41...
Reposted
@drpeedell.bsky.social please could you disseminate our survey to your colleagues. We are trying to use prediction models to help provide better info to pts when they make their treatment decisions but want to design them so they are useful qualtrics.ucl.ac.uk/jfe/form/SV_...
LUCID Survey
Qualtrics sophisticated online survey software solutions make creating online surveys easy. Learn more about Research Suite and get a free account today.
qualtrics.ucl.ac.uk
March 12, 2025 at 8:28 AM
@drpeedell.bsky.social please could you disseminate our survey to your colleagues. We are trying to use prediction models to help provide better info to pts when they make their treatment decisions but want to design them so they are useful qualtrics.ucl.ac.uk/jfe/form/SV_...
Reposted
New Podcast Alert! BTOG Does ... HER2.
Featuring @tnewsomdavis.bsky.social, Dr Emma O'Dowd and Dr Riyaz Shah, listen wherever you get your podcasts (search 'BTOG') or online www.btog.org/btog-podcasts/ .
Featuring @tnewsomdavis.bsky.social, Dr Emma O'Dowd and Dr Riyaz Shah, listen wherever you get your podcasts (search 'BTOG') or online www.btog.org/btog-podcasts/ .
March 13, 2025 at 9:36 AM
New Podcast Alert! BTOG Does ... HER2.
Featuring @tnewsomdavis.bsky.social, Dr Emma O'Dowd and Dr Riyaz Shah, listen wherever you get your podcasts (search 'BTOG') or online www.btog.org/btog-podcasts/ .
Featuring @tnewsomdavis.bsky.social, Dr Emma O'Dowd and Dr Riyaz Shah, listen wherever you get your podcasts (search 'BTOG') or online www.btog.org/btog-podcasts/ .
Reposted
📊 40% of #lungcancer patients say they didn’t get enough details about their diagnosis.*
📊 22% of UK EGFR+ patients don’t know their mutation type—even though it affects treatment.**
Patients can’t make informed choices without the right info. #LCSM
* LuCE 9th Report
** EGFR+ UK member survey
📊 22% of UK EGFR+ patients don’t know their mutation type—even though it affects treatment.**
Patients can’t make informed choices without the right info. #LCSM
* LuCE 9th Report
** EGFR+ UK member survey
March 11, 2025 at 8:31 AM
📊 40% of #lungcancer patients say they didn’t get enough details about their diagnosis.*
📊 22% of UK EGFR+ patients don’t know their mutation type—even though it affects treatment.**
Patients can’t make informed choices without the right info. #LCSM
* LuCE 9th Report
** EGFR+ UK member survey
📊 22% of UK EGFR+ patients don’t know their mutation type—even though it affects treatment.**
Patients can’t make informed choices without the right info. #LCSM
* LuCE 9th Report
** EGFR+ UK member survey
Reposted
“We’re talking about people’s lives, not just pathways. If it was your life on the line you wouldn’t settle for 64 days of waiting.” Patient perspective on waits for genomic testing in #lungcancer at #BTOG25
March 4, 2025 at 10:24 AM
“We’re talking about people’s lives, not just pathways. If it was your life on the line you wouldn’t settle for 64 days of waiting.” Patient perspective on waits for genomic testing in #lungcancer at #BTOG25
Reposted
At #BTOG25, our Chair, Debra Montague, addressed: Have we lost the patient voice in genomics? #lungcancer patients must be at the heart of genomic advances. With the focus often on technology & turnaround times, this was a chance to put patient experiences at the centre of the conversation.
#LCSM
#LCSM
March 4, 2025 at 11:44 AM
At #BTOG25, our Chair, Debra Montague, addressed: Have we lost the patient voice in genomics? #lungcancer patients must be at the heart of genomic advances. With the focus often on technology & turnaround times, this was a chance to put patient experiences at the centre of the conversation.
#LCSM
#LCSM
Reposted
‼️ 1 day until #BTOG25 ‼️
Things to look forward to #11
Solange Peters on Tuesday morning: patient selection for neoadj / perioperative SACT.
Previous ESMO President, IASLC board member, ETOP Founder, and all round global superstar.
Fantastic that we have lured her to Belfast
Things to look forward to #11
Solange Peters on Tuesday morning: patient selection for neoadj / perioperative SACT.
Previous ESMO President, IASLC board member, ETOP Founder, and all round global superstar.
Fantastic that we have lured her to Belfast
March 2, 2025 at 9:02 AM
‼️ 1 day until #BTOG25 ‼️
Things to look forward to #11
Solange Peters on Tuesday morning: patient selection for neoadj / perioperative SACT.
Previous ESMO President, IASLC board member, ETOP Founder, and all round global superstar.
Fantastic that we have lured her to Belfast
Things to look forward to #11
Solange Peters on Tuesday morning: patient selection for neoadj / perioperative SACT.
Previous ESMO President, IASLC board member, ETOP Founder, and all round global superstar.
Fantastic that we have lured her to Belfast
Reposted
Biomarker-selected or biomarker-agnostic ADCs for oncogene-addicted #NSCLC❓
💡Just out in @myESMO #CancerTreatmentReviews a comprehensive overview on current landscape, challenges and perspectives
Grateful to work with a global amazing team 🙏
Link to the Review:👇
doi.org/10.1016/j.ctrv…
💡Just out in @myESMO #CancerTreatmentReviews a comprehensive overview on current landscape, challenges and perspectives
Grateful to work with a global amazing team 🙏
Link to the Review:👇
doi.org/10.1016/j.ctrv…
February 16, 2025 at 6:53 PM
Biomarker-selected or biomarker-agnostic ADCs for oncogene-addicted #NSCLC❓
💡Just out in @myESMO #CancerTreatmentReviews a comprehensive overview on current landscape, challenges and perspectives
Grateful to work with a global amazing team 🙏
Link to the Review:👇
doi.org/10.1016/j.ctrv…
💡Just out in @myESMO #CancerTreatmentReviews a comprehensive overview on current landscape, challenges and perspectives
Grateful to work with a global amazing team 🙏
Link to the Review:👇
doi.org/10.1016/j.ctrv…
Reposted
Leaving X
I can’t continue to support X with a clear conscience.
I hope BlueSky replaces it. But I don’t think it will do so quickly unless we drop X, as opposed to us having feet in both camps.
I can’t continue to support X with a clear conscience.
I hope BlueSky replaces it. But I don’t think it will do so quickly unless we drop X, as opposed to us having feet in both camps.
February 7, 2025 at 8:27 AM
Leaving X
I can’t continue to support X with a clear conscience.
I hope BlueSky replaces it. But I don’t think it will do so quickly unless we drop X, as opposed to us having feet in both camps.
I can’t continue to support X with a clear conscience.
I hope BlueSky replaces it. But I don’t think it will do so quickly unless we drop X, as opposed to us having feet in both camps.
Reposted
Every day, 20 people in the UK are told they have #EGFR+ #lungcancer.
No one should have to face that alone. That’s why we’re here—to offer support, raise awareness, and push for earlier diagnosis.
Please support us with a donation if you can 💜 www.egfrpositive.org.uk/donate
#LCSM
No one should have to face that alone. That’s why we’re here—to offer support, raise awareness, and push for earlier diagnosis.
Please support us with a donation if you can 💜 www.egfrpositive.org.uk/donate
#LCSM
January 31, 2025 at 7:27 AM
Every day, 20 people in the UK are told they have #EGFR+ #lungcancer.
No one should have to face that alone. That’s why we’re here—to offer support, raise awareness, and push for earlier diagnosis.
Please support us with a donation if you can 💜 www.egfrpositive.org.uk/donate
#LCSM
No one should have to face that alone. That’s why we’re here—to offer support, raise awareness, and push for earlier diagnosis.
Please support us with a donation if you can 💜 www.egfrpositive.org.uk/donate
#LCSM
Reposted
Only 1.5% of #lungcancer research focuses on supportive & palliative care. Most people with lung cancer need this, yet it’s almost ignored. This has to change. Debra Montague, ALK+ UK Chair, says: ‘Research must go beyond survival & truly consider QoL.’ Read GLCC’s statement: shorturl.at/tYq1G #LCSM
January 28, 2025 at 7:13 AM
Only 1.5% of #lungcancer research focuses on supportive & palliative care. Most people with lung cancer need this, yet it’s almost ignored. This has to change. Debra Montague, ALK+ UK Chair, says: ‘Research must go beyond survival & truly consider QoL.’ Read GLCC’s statement: shorturl.at/tYq1G #LCSM
Reposted
Biomarker testing can help identify actionable mutations in patients with SqNSCLC, especially in those without a history of smoking. Testing is not performed consistently in this setting. #LCSM #lungcancer
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Comprehensive molecular profiling of squamous non-small cell lung cancer reveals high incidence of actionable genomic alterations among patients with no history of smoking
Next-generation sequencing (NGS) to detect actionable genomic driver alterations (AGAs) is critical to appropriate management of non-small cell lung c…
www.sciencedirect.com
January 19, 2025 at 3:58 PM
Biomarker testing can help identify actionable mutations in patients with SqNSCLC, especially in those without a history of smoking. Testing is not performed consistently in this setting. #LCSM #lungcancer
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
@goldstone-tony.bsky.social
Quick question, 23-24 TRS is in and my salary is down at the old one prior to DDRB pay awards (92k). Does it matter that it’s behind?
Quick question, 23-24 TRS is in and my salary is down at the old one prior to DDRB pay awards (92k). Does it matter that it’s behind?
January 15, 2025 at 7:56 PM
@goldstone-tony.bsky.social
Quick question, 23-24 TRS is in and my salary is down at the old one prior to DDRB pay awards (92k). Does it matter that it’s behind?
Quick question, 23-24 TRS is in and my salary is down at the old one prior to DDRB pay awards (92k). Does it matter that it’s behind?
Reposted
Time to summarize 10 years of MET amp research funishing with this recent one: www.lungcancerjournal.info/article/S016...
Genomic analysis of comprehensive next generation sequencing data to explore the criteria for MET amplification as an actionable biomarker in NSCLC
Amplification of the MET proto-oncogene receptor tyrosine kinase gene (MET) can be
both a de novo oncogenic driver or acquired resistance mechanism to non-MET directed
targeted therapy in other oncoge...
www.lungcancerjournal.info
January 14, 2025 at 3:25 AM
Time to summarize 10 years of MET amp research funishing with this recent one: www.lungcancerjournal.info/article/S016...
Reposted
Always enjoy these JTO "Controversies in Thoracic Oncology!" This issue's relevant debate of including adjuvant IO after neo-adj chemo/IO raises great points, reviews current data, highlights the unknown.
@drcamidge.bsky.social #LCSM
www.jto.org/article/S155...
www.jto.org/article/S155...
@drcamidge.bsky.social #LCSM
www.jto.org/article/S155...
www.jto.org/article/S155...
January 8, 2025 at 5:16 PM
Always enjoy these JTO "Controversies in Thoracic Oncology!" This issue's relevant debate of including adjuvant IO after neo-adj chemo/IO raises great points, reviews current data, highlights the unknown.
@drcamidge.bsky.social #LCSM
www.jto.org/article/S155...
www.jto.org/article/S155...
@drcamidge.bsky.social #LCSM
www.jto.org/article/S155...
www.jto.org/article/S155...